Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals

References

• Suboxone [prescribing information] Available from: http://www.suboxone.com/content/pdfs/SuboxonePI.pdfAccessed November 17, 2015
   Google Scholar
• Bunavail [prescribing information] Available from: http://www.bdsi.com/siteres.aspx?resid=5a738443-a797-41cd-a39a-a8deb2a4a585Accessed November 17, 2015
   Google Scholar
• BellJTrinhLButlerBRandallDRubinGComparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatmentAddiction20091041193120019563562
   PubMed Web of Science ®Google Scholar
• JonesESMooreBASindelarJLO’ConnorPGSchottenfeldRSFiellinDACost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patientsDrug Alcohol Depend20099913214018804923
   PubMed Web of Science ®Google Scholar
• FudalaPJBridgeTPHerbertSBuprenorphine/Naloxone Collaborative Study GroupOffice-based treatment of opiate addiction with a sublingual tablet formulation of buprenorphine and naloxoneN Engl J Med200334994995812954743
   PubMed Web of Science ®Google Scholar
• BagnolDMansourAAkilHWatsonSJCellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tractNeuroscience1997815795919300443
   PubMed Web of Science ®Google Scholar
• McKayJSLinakerBDTurnbergLAInfluence of opiates on ion transport across rabbit ileal mucosaGastroenterology1981802792846256253
   PubMed Web of Science ®Google Scholar
• FickelJBagnolDWatsonSJAkilHOpioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brainBrain Res Mol Brain Res199746189191072
   PubMedGoogle Scholar
• RangHPDaleMMRitterJMAnalgesic drugsPharmacology199913579603
   Google Scholar
• ThomasJOpioid-induced bowel dysfunctionJ Pain Symptom Manage20083510311317981003
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFO’ConnorMMossJRoizenMFGut motility and transit changes in patients receiving long-term methadone maintenanceJ Clin Pharmacol1998389319359807974
   PubMed Web of Science ®Google Scholar
• ThörnSEWattwilMLindbergGSäweJSystemic and central effects of morphine on gastroduodenal motilityActa Anaesthesiol Scand1996401771868848916
   PubMed Web of Science ®Google Scholar
• ManaraLBianchettiAThe central and peripheral influences of opioids on gastrointestinal propulsionAnnu Rev Pharmacol Toxicol1985252492733890704
   PubMed Web of Science ®Google Scholar
• ReberPBrenneisenRFlogerziBBatistaCNetzerPScheurerUEffect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphineDig Dis Sci20075250250717211696
   PubMed Web of Science ®Google Scholar
• HolzerPOpioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humansNeurosci Lett200436119219515135926
   PubMed Web of Science ®Google Scholar
• ManciniIBrueraEConstipation in advanced cancer patientsSupport Care Cancer199863563649695203
   PubMed Web of Science ®Google Scholar
• BenyaminRTrescotAMDattaSOpioid complications and side effectsPain Physician2008112 SupplS105S12018443635
   PubMed Web of Science ®Google Scholar
• MeissnerWSchmidtUHartmannMKathRReinhartKOral naloxone reverses opioid-associated constipationPain20008410510910601678
   PubMed Web of Science ®Google Scholar
• ThorpeDMManagement of opioid-induced constipationCurr Pain Headache Rep2001523724011309211
   PubMedGoogle Scholar
• KurzASesslerDIOpioid-induced bowel dysfunction: pathophysiology and potential new therapiesDrugs20036364967112656645
   PubMed Web of Science ®Google Scholar
• HolzerPTreatment of opioid-induced gut dysfunctionExpert Opin Investig Drugs200716181194
   PubMed Web of Science ®Google Scholar
• MelloNKMendelsonJBehavioral pharmacology of buprenorphineDrug Alcohol Depend1985142833033888577
   PubMed Web of Science ®Google Scholar
• PergolizziJAloisiAMDahanACurrent knowledge of buprenorphine and its unique pharmacological profilePain Pract20101042845020492579
   PubMed Web of Science ®Google Scholar
• LutfyKCowanABuprenorphine: a unique drug with complex pharmacologyCurr Neuropharmacol2004239540218997874
   PubMedGoogle Scholar
• MelloNKWalshSPrestonKStitzerMConeEBigelowGClinical pharmacology of buprenorphine: ceiling effects at high dosesClin Pharmacol Ther1994555695808181201
   PubMed Web of Science ®Google Scholar
• StrainECPrestonKLiebsonIBigelowGBuprenorphine effects in methadone-maintained volunteers: effect at two hours after methadoneJ Pharmacol Exp Ther19952726286387853176
   PubMed Web of Science ®Google Scholar
• YokellMAZallerNDGreenTCRichJDBuprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international reviewCurr Drug Abuse Rev20114284121466501
   PubMedGoogle Scholar
• JohnsonREJaffeJHFudalaPJA controlled trial of buprenorphine treatment for opioid dependenceJAMA1992267275027551578593
   PubMed Web of Science ®Google Scholar
• MattickRPBreenCKimberJDavoliMBuprenorphine maintenance versus placebo or methadone maintenance for opioid dependenceCochrane Database Syst Rev20142CD00220724500948
   PubMed Web of Science ®Google Scholar
• MaugerSFraserRGillKUtilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependenceNeuropsychiatr Dis Treat20141058759824741316
   PubMed Web of Science ®Google Scholar
• ZhouPLLiYLYanLDEffect of thienorphine on intestinal transit and isolated guinea-pig ileum contractionWorld J Gastroenterol2013191444145023539497
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationSuboxone Approval History Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20732,20733ltr.pdf
   Google Scholar
• FinchJWKamienJBAmassLTwo-year experience with buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice settingJ Addict Med2007110411021768942
   PubMed Web of Science ®Google Scholar
• SullivanJGWebsterLNovel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion studyClin Ther2015371064107525823919
   PubMed Web of Science ®Google Scholar
• VasishtNStarkJBaiSAFinnABuprenorphine/naloxone buccal film has a relative buprenorphine bioavailability approximately twice that of buprenorphine/naloxone sublingual tablet2014 ASAM 45th Annual Medical-Scientific Conference, Poster #10April 10–13, 2014Orlando, FL
   Google Scholar
• KaufmanPNKrevskyBMalmudLSRole of opiate receptors in the regulation of colonic transitGastroenterology198894135113562834257
   PubMed Web of Science ®Google Scholar
• DeHaven-HudkinsDLDeHavenRNLittlePJTechnerLMThe involvement of the µ-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptorPharmacol Ther200811716218718022696
   PubMed Web of Science ®Google Scholar
• DePriestAZMillerKOxycodone/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrencePain Ther2014311525135384
   PubMedGoogle Scholar
• SmithKHoppMMundinGNaloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteersExpert Opin Investig Drugs201120427439
   PubMed Web of Science ®Google Scholar
• Foxx-OrensteinAECamilleriMSzarkaLADoes co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trialNeurogastroenterol Motil20071982183017539894
   PubMed Web of Science ®Google Scholar
• WongBSRaoASCamilleriMThe effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in healthAliment Pharmacol Ther20103288489320839388
   PubMed Web of Science ®Google Scholar
• KuhlmanJJJrLevineBJohnsonREFudalaPJConeEJRelationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphineAddiction1998935495599684393
   PubMed Web of Science ®Google Scholar
• BrownSMHoltzmanMKimTKharaschEDBuprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically activeAnesthesiology20111151251126022037640
   PubMed Web of Science ®Google Scholar
• YassenAKanJOlofsenESuidgeestEDahanADanhofMPharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in ratsJ Pharmacol Exp Ther200732159860717283225
   PubMed Web of Science ®Google Scholar
• HuangPKehnerGBCowanALiu-ChenLYComparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonistJ Pharmacol Exp Ther200129768869511303059
   PubMed Web of Science ®Google Scholar
• Commonwealth of AustraliaAustralian Public Assessment Report for Buprenorphine/Naloxone Available from: https://www.tga.gov.au/auspar/auspar-buprenorphine-naloxoneAccessed March 9, 2016
   Google Scholar